ArticleWorld journal of experimental medicine2025
Safety and efficacy of autologous bone marrow aspirate concentrate injection for idiopathic male infertility: A comparative study.
Article in World journal of experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough limited clinical evidence exists, such as case reports of azoospermia treatment in humans using bone marrow aspirate concentrate (BMAC) injection, these findings provide a compelling foundation for exploring mesenchymal stem cell therapy in male infertility.
aimTo evaluate the safety and efficacy of autologous BMAC injection into human testis for men with severe oligospermia or azoospermia over the existing standard of care pharmacotherapy and lifestyle modifications.
methodsWe included patients diagnosed with male infertility of the age group between 35-45 years in this trial comparing BMAC injection therapy with pharmacotherapy and lifestyle modifications over a 6-month follow-up period. Semen analysis was used to evaluate the efficacy of the interventions analyzed.
resultsWe enrolled 30 patients in the trial with 10 patients in each arm of the trial. Compared to the baseline, neither the BMAC group (
conclusionThis trial highlights the potential of autologous BMAC as a promising therapeutic option for male infertility. Despite the absence of significant changes within individual treatment arms, BMAC therapy demonstrated superior efficacy in improving both sperm count and motility compared to standard pharmacotherapy and lifestyle modifications. These findings underscore the potential role of regenerative medicine in addressing severe oligospermia and azoospermia, warranting further research to solidify its clinical applicability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.